Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a 24-week, double-blind, U.S. Phase IIa trial in overweight or obese patients, Symlin plus metreleptin, a
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury